IR Overview

Tribute Pharmaceuticals Canada Inc.
(OTCQX: TBUFF) (TSXV: TRX)

Tribute Pharmaceuticals Canada Inc. (“Tribute”) is a leading Canadian specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US. The Company targets several therapeutic areas but has a particular interest in products for the treatment of pain, neurology, dermatology, cardiology, endocrinology and specialty care. Tribute also sells Uracyst® and NeoVisc® internationally through a number of strategic partnerships. Tribute currently markets NeoVisc® Single Dose, NeoVisc® Triple Dose, Uracyst®, Soriatane®, Bezalip® SR, Cambia®, Fiorinal®, Fiorinal® C, Visken® and Viskazide in Canada and has the US rights to Bezalip® SR and global rights to Uracyst® and NeoVisc® Additionally, Tribute has the exclusive Canadian rights to bilastine in Canada (not yet approved).


Recent News



Quick Links


Fact Sheet


Corporate Presentation

Investor Relations

Scott Langille
Chief Financial Officer
Tribute Pharmaceuticals Canada Inc.
519-434-1540
scott.langille@tributepharma.com

Transfer Agent

Equity Transfer Services Inc.
120 Adelaide St. W
Toronto, ON M5H 4C3
416-361-0152

Auditors

McGovern, Hurley, Cunningham, LLP
2005 Sheppard Avenue East
Suite 300
Toronto, ON M5H 3C2